Boca Raton, FL – November 10, 2026 – Akron Bio, a leading supplier of GMP-compliant materials and services for advanced therapies, announced today that it has entered into a definitive agreement to join MaxCyte. Bringing together almost 50 years of experience in the field of cell therapy, this acquisition will enable customers and partners with a broader set of solutions covering the breadth of the cell therapy workflow, streamlining the supply of critical technologies.
Over the past two decades, Akron has built a robust portfolio of ancillary materials designed for cell therapy manufacturing, pioneering the development of Closed System Solutions (CSS)® to streamline production and providing the regulatory support required to enable clinical and commercial programs globally. Akron’s acquisition by MaxCyte builds on this shared vision and aims to streamline the development and delivery of innovative, high-performance products essential for cell therapy research, clinical development, and commercial manufacturing.
“We are tremendously excited by the opportunity to join these two world-class organizations, leveraging our collective experience and expertise to support scientists and clinicians as they bring transformative therapies to patients around the world,” said Ezequiel Zylberberg, Akron’s Chief Operating Officer. “At Akron, we have always believed in earning our partners’ trust through consistent execution, uncompromising quality, and a deep commitment to the patients they serve. As part of MaxCyte, we remain committed to delivering the quality, reliability, and innovation our partners have come to expect.”
“Acquiring Akron is one of the most significant milestones in MaxCyte’s history,” said Maher Masoud, President and Chief Executive Officer of MaxCyte. “From day one, Akron provides us an established portfolio of clinical and commercial programs supported by Akron’s drug master file and reagents while expanding MaxCyte’s reach across the cell therapy workflow. Importantly, Akron is profitable today and nearly doubles our revenue base while significantly accelerating our path to profitability. Similar to MaxCyte, Akron built itself as a leading cell therapy tools company by providing high-quality differentiated cytokines, growth factors, blood products and media. We are very excited to work alongside the talented Akron team as we bring our two best-in-class companies together to deepen customer relationships and better support cell and gene therapy developers from development through commercialization.”
The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing characterization assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine.
About Akron Bio
Akron Bio is a leading provider of critical materials and manufacturing services supporting the development and commercialization of cell and gene therapies. Through its portfolio of cytokines, growth factors, human plasma-derived products, specialty media, and comprehensive manufacturing services for complex and specialized reagents, Akron empowers therapy developers to advance promising discoveries into scalable, commercial therapies. From early development through commercialization, Akron provides the quality, regulatory support, supply reliability, and manufacturing expertise its partners need to advance therapies with confidence and ultimately serve patients with critical unmet needs. For more information, please visit www.akronbiotech.com.
For further information, please contact:
Akron Contacts:
Akron Bio Media Relations:
brichardson@akronbiotech.com
MaxCyte Contacts:
Investor Relations
Gilmartin Group
Erik Abdow
ir@maxcyte.com
Media Contact
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com